Augusta University Student Health Services

706-721-3448 immunizations@augusta.edu

Name:		
Date of Birth:		
Student ID:		

AUGUSTA UNIVERSITY CERTIFICATE OF IMMUNIZATION

Your health care provider must complete and sign this form. All information must be written in English.

This document must be submitted at least two (2) weeks prior to registration.

Please follow the directions at http://www.augusta.edu/shs/immunizations.php to submit your record.

Vaccine	Date: M/DD/Y	YYY		REQUIRED FOR & WHAT is needed			
MMR (measles, mumps, rubella)	#1://_ #2://_		REQUIRED for students born after Jan. 1, 1957: vaccine or antibody titer. WHAT: Two (2) doses of combined measles-mumps- rubella or "MMR" or separate vaccines for each measles, mumps, and rubella. The first dose of all vaccine types must be given at 12 months of age or later and the second dose of the MMR, measles, mumps at least 28 days after the first dose OR - Attach copy of lab report of IgG blood antibody titer results for each virus: measles, mumps, rubella as evidence of immunity.				
#1://			REQUIRED for all students. WHAT: 2 doses given at least 3 months apart if both doses are given before age 13 OR - 2 doses at least 4 weeks apart if first dose is given after 13th birthday OR - documented history by physician of chicken pox or shingles OR - Attach copy of lab report of IgG antibody titer results as evidence of immunity.				
Tetanus, Diphtheria, Pertussis (TDaP) If TDaP is > 10 years old, date of last Tetanus booster:		•	REQUIRED for all students. WHAT: One Tdap dose administered after 6/10/2005. If TDaP is was administered more than 10 years ago, then a Td booster dose is ALSO required.				
Hepatitis B	#1:/			REQUIRED for all students who will be 18 years of age or less at the time of expected enrollment date WHAT: 3 dose of hepatitis B series (given at 0, 1-2, and 4-6 months) OR -3 dose combined hepatitis A and hepatitis B series (at 0, 1-2 and 6-12 months) OR -2 dose hepatitis B series of Recombivax (at 0 and 4-6 months) given at 11-15 years of age OR -Attach copy of lab report of Hep B surface antibody titer results.			
Tuberculosis (TB)	uberculosis (TB) TB Screening Questionnaire on Page 2		REQUIRED : All students must complete the "TB screening questionnaire" on page 2.				
Meningococcal (ACWY (MCV4) #1/ & #2:/ if initial dose more than 5 years ago		REQUIRED: All students living in on-campus housing or sorority/fraternity housing. WHAT: One dose if unvaccinated. If initial dose given more than 5 years ago, a booster is require A student may sign a waiver and statement of understanding by going to: https://www.augusta.edu/shs/immunizationwaivers.php					
STRONGLY RECOM	MENDED IMMUNIZ	ATIONS (NOT F	REQUIRED):				
	te: MM/DD/YY	Date: MM/DD/		Date: MM/DD/YY	Notes:		
COVID-19	/ /	/	/	/ /	Туре:		
Hepatitis A	/ /	/	/ Strongly recommended if travel outside of U.S.				
Meningococcal B			/	/ /	(Bexsero or Trumenba – circle type given)		
HPV	/ /	/ /		/ /	males and females through age 45 years		
Influenza	/ /				-		
_	he above informati		_	-	nation to Augusta University Student HealthDate:		
	ATURE OF licensed			NN*			
Address:			Ph	one:			

Signature: _____ Date: _____

^{*} Healthcare Clinician can be a U.S. licensed physician, nurse practitioner, physician assistant or registered nurse.

Augusta University Student Health Services

706-721-3448 immunizations@augusta.edu

Name:	 		
Date of Birth:			
Student ID: _			

		SITY CERTIFICATE OF IM			
	https://www.aug	usta.edu/shs/documents/undergradf	orm.pdf		
Please answer th	nese questions –by checking the a	ppropriate box ("Yes" or "No")	:		
1. Have you had c	lose contact with persons known or	suspected to have active TB?		□ Yes	□ No
2. Were you born	in one of the countries listed below	that have a high incidence of acti	ve TB?	□ Yes	□ No
· · · · · · · · · · · · · · · · · · ·	rcle the country below.	, and the second			
Afghanistan	Côte d'Ivoire	Japan	Nicaragua		Sudan
Algeria	Croatia	Kazakhstan	Niger		Suriname
Angola	Democratic People's Republic	Kenya	Nigeria		Tajikistan
Argentina	Korea	Kiribati	Pakistan		Thailand
Armenia	Democratic Republic of the	Kuwait	Palau		Timor-Leste
Azerbaijan	Congo	Kyrgyzstan	Panama		Togo
Bahrain	Djibouti	Lao People's Democratic	Papua New Guinea		Yokelau
Bangladesh	Dominican Republic	Republic	Paraguay		Tunisia
Belarus	Ecuador	Latvia	Peru		Turkmenistan
Belize	El Salvador	Lesotho	Philippines		Tuvalu
Benin	Equatorial Guinea	Liberia	Poland		Uganda
Bhutan Bolivia (Plurinational S	Eritrea State Estonia	Libyan Arab Jamahiriya Lithuania	Portugal		Ukraine Un. Rep. of Tazania
Bosnia and Herzegovin		Madagascar	Qatar Republic of Korea		Uruguay
Botswana	Fiji	Malawi	Republic of Moldova		Uzbekistan
Brazil	Gabon	Malaysia	Romania		Venezuela (Bol. Rep.)
Brunei Darussalam	Gambia	Maldives	Russian Federation		Vietnam
Bulgaria	Georgia	Mali	Rwanda		Yemen
Burkina Faso	Ghana	Marshall Islands	Saint Vincent and the		Zambia
Burundi	Guam	Mauritania	Grenadines		Zimbabwe
Cambodia	Guatemala	Mauritius	Sao Tome and		
Cameroon	Guinea	Micronesia (Federated States	Senegal		
Cape Verde	Guinea-Bissau	of)	Seychelles		
Central African Republ	ic Guyana	Mongolia	Sierra Leone		
Chad	Haiti	Morocco	Singapore		
China	Honduras	Mozambique	Solomon		
Colombia	India	Myanmar	Somalia		
Comoros	Indonesia	Namibia	South Africa		
Congo	Iraq	Nepal	Sri Lanka		
If yes, <u>check</u> the	requent or prolonged visits to one or e applicable countries. a resident and/or employee of high-i			□ Yes	
=		isk congregate settings (e.g., com	ectional facilities, fion		□ No
long-term care	•				_
	a volunteer or healthcare worker wh	no served clients/patients who we	ere at increased risk fo		
TB disease?					□ No
6. Have you ever l	been a member of any of the followi	ng groups that may have an incre	ased incidence of late	nt or act	tive
TB disease: med	dical underserved, low-income, or al	ousing drugs or alcohol?		□ Yes	□ No
7. Have you ever l	nad a positive TB skin test or IGRA bl	ood test?		□ Yes	□ No
•	ne BCG* vaccination?			□ Yes	□ No
	ation is a vaccine for TB that is typically g	given in foreign countries with a highe	er incidence of TR For m		
	ccine, visit: <u>https://www.cdc.gov/vaccin</u> e		T Incluence of TB. FOI III	ore mjorn	Hation
regulating this va	cerre, visit. <u>inteps.//www.cuc.gov/vuccine</u>	<u></u>			
ATTECTATION	TERAFRIT.				
ATTESTATION STA	ATEIVIENT:				

<u>A</u>

I attest that the above information is accurate.

Student Signature:	Date:	
--------------------	-------	--

Augusta University Student Health Services

706-721-3448 immunizations@augusta.edu

Name:	 	
Date of Birth:		
Student ID: _	 	

CLINICAL ASSESSMENT BY HEALTHCARE CLINICIANS

ı	Diagon.	review and wrife the TD Overtisms in manager of any anagement "VEC", they are readily to favorith and the rest
		review and verify the TB Questionnaire responses. If any are answered "YES", they are candidates for either tuberculin skin test
		feron Gamma Release Assay (IGRA) unless a previous positive test has been documented.
	-	of positive TB skin test or IGRA blood test? \Box Yes (document below) \Box No
	History	of BCG vaccination? Yes (consider IGRA if possible) No
3.	TB Sym	ptoms Check: Does the student have signs or symptoms of active pulmonary TB disease? ☐ Yes ☐ No
1.	Proceed	d with further tests to exclude active TB, including chest X-ray as medically indicated.
_		stic/screening tests:
•	_	
		Tuberculin Skin Test (TST):
		 Date Given: Date Read: Skin test result = mm induration; interpretation* = □ positive □ negative
		 Skin test result =mm induration; interpretation* = □ positive □ negative
	>	Interferon Gamma Release Assay (IGRA) (Required if TST is positive. Lab report must be attached)
		Date obtained:// Specify method: □ QFT-GIT □ T-spot □ other
		Result: Positive Negative Indeterminate borderline (T-spot only)
	_	
		Chest X-ray (required if IGRA is positive):
		• Date of chest X-ray:/ Result: □ normal □ abnormal (acute pulmonary TB)
	*TCT 100	tornrotation guidalines
		terpretation guidelines:
	_	is positive:
	0	recent close contacts of an individual with infectious TB persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease
	0	organ transplant recipients and other immunocompromised persons
		is positive:
		recent arrival to the U.S. (<5 years) from high prevalence areas
	0	injection drug users
	0	Mycobacteriology lab personnel
	0	residents, employees, or volunteers in high-risk congregate settings
	0	persons with medical conditions that increase the risk of progression to TB disease, including
		immunosuppressive disorders, silicosis, diabetes mellitus, chronic renal failure, and certain types of
		cancer (e.g., leukemias and lymphomas, cancers of head/neck/lung), gastrectomy or jejunoileal
	> 1E mm	bypass, weight loss > 10% below ideal body weight. is positive:
	○ 7 12 IIIIII	persons with no known risk factors for TB
	Ü	persons with no known risk factors for 15
RFC	UIRFD	SIGNATURE OF HEALTHCARE CLINICIAN*
Jan	20.	Address: Phone:
vaii	iie	Address Priorie:
igr	nature: _	Date:

^{*} Healthcare Clinician can be a U.S. licensed physician, nurse practitioner, physician assistant or registered nurse.